A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours by Yasutoshi Kuboki, Hendrik-Tobias Arkenau, Vivek Subbiah, Timothy Price, Gerald Falchook, Hans Prenen, Rafal Dziadziuszko, Hansen Wong, Iwona Lugowska, Daniel Tan, Weibing Shi, Ryota Shibaki, Min Hee Hong, Sant P Chawla, Jose G Monzon, Mun Hui, Caio Max Rocha Lima, Kejia Wang, Antreas Hindoyan, Mira Kistler

Get full text